PDT Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

PDT Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,806	Closed	-$490K	–	708
2023 Q2	$490K	Sell	4,806 -38,343	-89%	-$3.63M	0.07%	381
2023 Q1	$3.92M	Buy	43,149 +5	+0%	+$293	0.53%	21
2022 Q4	$1.64M	Sell	43,144 -14,990	-26%	-$516K	0.27%	120
2022 Q3	$1.46M	Sell	58,134 -5,130	-8%	-$142K	0.22%	127
2022 Q2	$1.92M	Buy	63,264 +52,907	+511%	+$1.58M	0.17%	183
2022 Q1	$339K	Buy	+10,357	New	+$307K	0.03%	686

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PDT Partners's RETA Position: Q3 2023 in Review

PDT Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 4,806 shares — an estimated $490K sold.

PDT Partners first reported a position in RETA in Q1 2022 and held it in 6 quarters. The position peaked at $3.92M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

PDT Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
PDT Partners sold 4,806 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $490K.
PDT Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 6 quarters.
PDT Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.92M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on PDT Partners's 13F filing for Q3 2023, filed 14 Nov 2023.